Nils Koch-Henriksen
Overview
Explore the profile of Nils Koch-Henriksen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
2000
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lorscheider J, Signori A, Subramaniam S, Benkert P, Vukusic S, Trojano M, et al.
J Neurol Neurosurg Psychiatry
. 2024 Dec;
PMID: 39643429
Background: Effectiveness of disease-modifying treatment (DMT) in people affected by primary progressive multiple sclerosis (PPMS) is limited. Whether specific subgroups may benefit more from DMT in a real-world setting remains...
2.
Soelberg Sorensen P, Bramow S, Magyari M, Werdelin L, Koch-Henriksen N, Vermersch P, et al.
Mult Scler
. 2024 Mar;
30(6):623-629.
PMID: 38523325
Torben Fog was committed to multiple sclerosis (MS) research for more than four decades, starting before the defence of his thesis in 1948 and lasting until his death in 1987....
3.
4.
Signori A, Lorscheider J, Vukusic S, Trojano M, Iaffaldano P, Hillert J, et al.
J Neurol Neurosurg Psychiatry
. 2022 Sep;
94(1):23-30.
PMID: 36171104
Background: Over the decades, several natural history studies on patients with primary (PPMS) or secondary progressive multiple sclerosis (SPMS) were reported from international registries. In PPMS, a consistent heterogeneity on...
5.
Magyari M, Joensen H, Kopp T, Pontieri L, Koch-Henriksen N
Mult Scler
. 2022 Jul;
28(14):2190-2201.
PMID: 35822309
Background: The course of multiple sclerosis (MS) appears to be milder in recent decades. Objective: To investigate how time from onset to disability milestones and how demographic and clinical characteristics...
6.
Magyari M, Koch-Henriksen N
J Neurol Neurosurg Psychiatry
. 2022 Apr;
93(7):716-722.
PMID: 35393340
Objective: To quantify sex differences in activity and severity of multiple sclerosis (MS) and how it depends on disease duration and time since clinical onset. Methods: All Danish citizens with...
7.
Koch-Henriksen N, Magyari M
Nat Rev Neurol
. 2021 Sep;
17(11):676-688.
PMID: 34584250
Multiple sclerosis (MS) is an immunological disease that causes acute inflammatory lesions and chronic inflammation in the CNS, leading to tissue damage and disability. As awareness of MS has increased...
8.
Koch-Henriksen N, Soelberg Sorensen P, Magyari M
Mult Scler Relat Disord
. 2021 Jun;
53:103029.
PMID: 34116481
Objective: Whether relapses have direct effects on permanent disability in multiple sclerosis is still an unsettled issue. We aimed at investigating the cumulative effect of breakthrough relapses on the Expanded...
9.
Andersen J, Sharmin S, Lefort M, Koch-Henriksen N, Sellebjerg F, Soelberg Sorensen P, et al.
Mult Scler Relat Disord
. 2021 Jun;
53:103012.
PMID: 34116480
Background: Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsing-remitting multiple sclerosis. Of three published head-to-head studies two showed that natalizumab is the more...
10.
Iaffaldano P, Lucisano G, Butzkueven H, Hillert J, Hyde R, Koch-Henriksen N, et al.
Mult Scler
. 2021 Apr;
27(10):1543-1555.
PMID: 33900144
Background: The optimal timing of treatment starts for achieving the best control on the long-term disability accumulation in multiple sclerosis (MS) is still to be defined. Objective: The aim of...